On September 25, 2019, LEAPS will hold a virtual design webinar to refine key features of the initial core evidence generation platforms for its pilot phase. Here's a snapshot of the project, and a glimpse behind the curtain for this important working session:
PURPOSE of LEAPS: To advance the mission of NEWDIGS – to deliver more value faster to patients, in ways that work for all stakeholders – through a new collaborative approach to the planning, production, and use of real world evidence. Success in LEAPS targets improved patient outcomes while also reducing waste and inefficiency across the system.
PILOT: A model system for Rheumatoid Arthritis will be piloted using Massachusetts as a statewide testbed. Rollout will begin in 2020. A V1.0 pilot Blueprint, and a generalizable design Playbook (for application by innovators in other disease areas and geographies) will be available in Q1 2020.
PLATFORMS: The application of platform strategies to advance the efficiency, scale, and sustainability of real world evidence production is central to LEAPS. The initial core platforms for the pilot include: (1) Real World Discovery Platform, designed to fuel hypothesis generation related to the identification of clinically meaningful patient subpopulations, and eventually, “composite” predictive markers (i.e., “omics + clinical/socioeconomic), and (2) Adaptive Point of Care Platform, designed to improve decisions about treatment selection, switching, and sequencing. These will be separate infrastructures but coordinated to address different questions with a shared goal: to improve decision making related to getting the right treatment to the right patient at the right time (i.e., regimen optimization over the trajectory of the disease).
LEAPS' multi-stakeholder design teams now preparing for the webinar will build on the session outputs for our December 2019 Design Lab. This webinar is by invitation only. LEAPS remains open to new organizational members - for further information contact Kay Larholt at klarholt@,mit.edu.